COMP <GO>
ASTH vs EFOR // REVENUE GROWTH (YOY)
Astrana Health Inc. (NASDAQ) VS. Everforth Inc. (NYSE) • 15-METRIC TALLY: ASTH 4
— EFOR 8
▲ REVENUE GROWTH (YOY) LEADER: ASTH
LAST: $36.62 (-0.14%) • MKT CAP: $1.82B
revenue-growth
56.40%
LAST: $37.01 (-4.47%) • MKT CAP: $1.52B
revenue-growth
-2.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASTH VS. EFOR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ASTH | EFOR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 28.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.60% | 6.50% | -1.90 | EFOR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 27.3x | 9.6x | +17.70 | EFOR | /valuation <GO> |
| Free Cash Flow Yield | 5.75% | 18.99% | -13.24 | EFOR | /fcf-yield <GO> |
| Operating Margin | 2.50% | 5.80% | -3.30 | EFOR | /operating-margins <GO> |
| Net Profit Margin | 0.80% | 2.90% | -2.10 | EFOR | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 56.40% | -2.90% | +59.30 | ASTH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.43% | 0.00% | +0.43 | ASTH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.54 | 2.35 | +0.19 | ASTH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | EFOR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 52.5 | -5.81 | EFOR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 63.6x | 12.5x | +51.10 | EFOR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.82B | $1.52B | $299.1M | ASTH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ASTH REV | EFOR REV | ASTH GROSS % | EFOR GROSS % | ASTH FCF | EFOR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $3.98B | — | 28.9% | $104.5M | $288.1M |
| FY 2024 | $2.03B | $4.10B | — | 28.9% | $44.2M | $364.7M |
| FY 2023 | $1.39B | $4.45B | — | — | $68.2M | $456.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASTH // BETA —
EFOR // BETA —